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Glioblastoma multiforme (GBM) is the most prevalent and aggressive malignant primary 
brain tumor in humans. Once diagnosed, patient survival times range from three months if left 
untreated to a 12 percent survival rate at two years with palliative treatment. Death is usually 
a result of cerebral edema and increased intracranial pressure associated with a necrotic mass. 
Treatment of GBM is very difficult due to the vulnerability of healthy brain tissue to 
conventional treatments and the restricted ability of the brain to repair itself, as well as the 
difficulties associated with administering chemotherapeutic agents across the blood brain 
barrier. Treatment with gamma irradiation and chemotherapy concurrently has been shown to 
significantly improve patient survival rates when compared to tumor resection alone 
(Patwardhan et. al., 2004). The expression of apoptosis genes in response to treatment with 
cisplatin or a combination cisplatin and gamma irradiation in two GBM cell lines, U87 and U251, 
was investigated by quantitative real time polymerase chain reaction (qPCR). Ideally, up 
regulation of genes associated with pro-apoptotic pathways and down regulation of genes 
associated with anti-apoptotic pathways would increase levels of programmed cell death by 
apoptosis, as opposed to necrosis. This may result in decreased cerebral edema and pressure, 
thereby increasing patient survival rates.
Introduction
Glioblastoma Multiforme (GBM) is the most prevalent and aggressive malignant primary 
brain tumor in humans (CBTRUS, 2011). Once diagnosed, the patient's prognosis is grim. Due 
to the aggressive nature of GBM, survival times range from three months if untreated, to an 
average of 1-2 years with palliative treatment. Treated patients have only a twelve percent 
survival rate at two years and median survival of only 15 months (CBTRUS, 2011). Death is 
usually a result of cerebral edema and increased intracranial pressure associated with a 
necrotic mass. Treatment of GBM is very difficult for several reasons. First, the GBM cells are 
very resistant to conventional therapies and healthy brain tissue is vulnerable to these 
therapies. This can have a detrimental effect on the brain, given the restricted ability to repair 
itself (Lawson et al., 2007). Another consideration in treating GBM with chemotherapeutic 
agents is the decreased efficiency or inability of large molecules to cross the blood brain barrier 
and effectively target the tumor cells.
Treatment of GBM cells by gamma irradiation and chemotherapy concurrently has been 
shown to significantly improve patient survival rates when compared to tumor resection alone 
(Patwardhan et al., 2004). The effects of gene regulation on patient survival are unclear at this 
time. However, apoptosis array analysis may provide insight into how GBM cells die by 
apoptosis after undergoing various treatments. Ideally, the treatments would up regulate pro- 
apoptotic genes and down regulate anti-apoptotic genes, promoting increased levels of 
apoptosis and reduced levels of necroptosis (Castellino et al., 2007). Programmed cell death as 
a result of apoptosis may lead to increased patient survival by decreasing edema and 
intracranial pressure associated with necrotic cell death.
wTwo GBM cell lines were used In this study. The U87 cell line is wild type for the p53 gene, 
an essential tumor suppressor gene capable of regulating cell cycle. The U251 cell line is 
defective in the p53 gene (van Meir et al., 1994). Cells from each tumor line have been 
cultured, treated, collected and have undergone quantitative real time polymerase chain 
reaction using 96-well Human RT2 Apoptosis qPCR Arrays (Qiagen) to analyze and determine 
the regulation of 84 genes associated with apoptosis as a result of treatment with cisplatin or a 















Human tissue samples. U87 and U251 GBM cell lines were obtained from Dr. David Grdina 
and Dr. Jeff Murley at the University of Chicago and Dr. Howard Fine at the National Institutes 
of Health. The cell lines were originally obtained from a stage three tumor in a 44 year old 
Caucasian female. The tumor expressed both U87 tumor cells and U251 tumor cells expressing 
a mutation of the p53 gene, causing it to be present but dysfunctional (van Meir et al., 1994).
Cell Culture and Collection. GBM cells were maintained in monolayer culture in DMEM-F12 
(1:1) medium supplemented with 10% fetal bovine serum and penicillin/streptomycin and 
incubated at 37°C in a humidified atmosphere containing 5% C 0 2 and 95% air. The followingI
cell doubling times were obtained using similar conditions to those described above: U87 cells 
exhibited doubling times of 29.8 hours, whereas U251 cdlls doubled in quantity slightly faster, 
within 25.9 hours (Ke et al., 2000). Growth medium was discarded from T75 flask after a 
maximum of three days and replenished with lO m L fresh 37°C DMEM:F12. Cells were 





and 0.02% EDTA for 6 minutes for U251 cells and 3 minutes for U87 cells (Gupta et al.,1997; 
Yasui et al., 2008). Cells were then collected into centrifuge tubes, pelleted by centrifugation 
(1000 rpm, 2 minutes, 12°C) and resuspended in fresh medium for counting. The number of 
cells obtained was calculated by viewing lO pL of cell suspension on a hemocytometer under an 
inverted microscope. The hemocytometer count was then divided by four and multiplied by 
10,000 to determine the number of cells per milliliter in the sample. Approximately 150,000 
cells were replated onto the T75 flask to be maintained in a monolayer culture. T75 flasks were 
trypsinized a maximum of three times before being discarded, at which time cells were plated 







Serial dilutions were performed in order to obtain required concentrations for seeding onto 
100mm and 60mm Petri plates. See Table 8 for the plating concentrations used in the 
experimental trials. Growth medium was collected into 50mL centrifuge tubes from the Petri 
plates prior to trypsinization in order to collect floating cells. Cells were trypsinized as 
previously described and collected into the same 50mL centrifuge tubes. Two milliliters of fresh 
medium were added to the Petri plates, which were then carefully scraped with rubber 
policemen to avoid overlapping scraped areas. Dislodged cells remained intact for collection. 
The vials were pelleted by centrifugation, medium was removed and cell pellets were 
resuspended in fresh medium to give approximate concentrations of less than 1 x 106 cells per 
milliliter. Exact concentrations were determined by hemocytometer count. Cells were divided 
and collected in 15mL centrifuge tubes to obtain approximately 1-2 x 106 cells per tube. 
Samples were pelleted by centrifugation, medium was removed and cells were resuspended 
and washed in lm L  PBS. The cell suspensions were then transferred to 1.5mL microfuge tubes
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using a pipetman and microfuged at 16,000 x g to repellet. PBS was carefully pipetted off of the 
pellets. Labeled microfuge tubes were then placed into the -80°C freezer for at least 10 
minutes prior to RNA isolations.
Cisplatin Treatment and Coliection. Cells from each tumor line were subcultured onto 
100mm and 60mm Petri plates containing lOm L and 5mL growth medium, respectively. Several 
dilutions of cells were plated onto the Petri plates according to the length and type of 
treatment subjected to. Tables 1 and 2 show the plating dilutions and collection totals for the 
experimental conditions in both U87 and U251 cell lines.
Two experimental conditions were established using cisplatin. The first condition applied 
only a lp M  cisplatin-growth medium solution for a period of either three days or seven days of 
continuous exposure. The second experimental condition also included continuous exposure to 
a lp M  cisplatin-growth medium solution, as well as 10 Gray gamma irradiation, as described 
below.
The lp M  cisplatin-growth medium solution was prepared first as a 2mM cisplatin-PBS 
solution by the addition of 5mg cisplatin to 8.3mL PBS solution. The lp M  solution was 
prepared by the addition of 50pL of the 2mM cisplatin-PBS solution per lOOmL of growth 
medium. The original growth medium in the plates designated for treatment with cisplatin was 
discarded and lO m L of the lp M  cisplatin-growth medium solution were added to each of the 
100mm Petri plates. The cells on the 60mm Petri plates were treated with 5mL of the lp M  
cisplatin-growth medium solution.
The Petri plates were then returned to the incubator. After three or seven days the
cisplatin-growth medium was collected into 50mL centrifuge tubes prior to trypsinization to
collect floating cells. The plates were then trypsinized as previously described for experimental
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conditions. After pelleting by centrifugation, the cisplatin-medium solution was decanted into 
the cisplatin waste container and the pellet was resuspended in fresh growth medium to 
determine cell count. The cells were again separated into separate 15mL centrifuge tubes to 
obtain 1-2 x 106 cells per vial, pelleted by centrifugation and resuspended in lm L  PBS. Once 
washed with PBS, the cells were transferred into 1.5mL microfuge tubes, pelleted at 16,000 x g 
and PBS was carefully pipetted off. Microfuge tubes were labeled and stored in -80°C freezer 
prior to RNA isolations.
Gamma Irradiation and Collection. U251 cells were subcultured onto 60mm Petri plates 
with 5mL growth medium at varying concentrations according to Tables 1 and 2. Treatments 
with gamma irradiation were only conducted in conjunction with lp M  cisplatin treatments.
Gamma irradiation was delivered by subjecting three stacked 60mm Petri plates to a 
Cesium-137 gamma source for five minutes and sixteen seconds. (Dose rate 1.9 Gray/minute) 
The cells were treated with gamma irradiation three hours after receiving the 5m L of lp M  
cisplatin-growth medium solution. The cells were trypsinized and collected, as described 
above, after three days or seven days of continuous exposure to lp M  cisplatin-growth medium  
solution. The cells were labeled and stored in -80°C freezer until RNA isolations were 
performed.






Cells Plated CollectionDate Total Cells
100,000 x l 20111202 1.43 x 10
200,000 x l 20111202 1.46 x 10
150,000 x2 20111202 1.02 x 10
7 Day Collections
Cells Plated CollectionDate Total Cells
20,000x2 20111206 3.74 x 10
20,000x3 20111206 1.07 x 10











Cells Plated CollectionDate Total Cells
50,000x2
20120205 1.71 x 106
100,000 x2
100,000 x6 20120206 1.57 x 106
150,000 x l
20120206 1.16 x 106200,000 x5
250,000 x l
7 Day Collections





20120210 2.35 x 106
40,000 x2
150,000x3


















RAM Isolation. RNA isolations procedures were performed using an Ambion PureLink 
RNA Mini Kit (Catalog No. 12183-018A, lot 844860) according to the protocols for samples of 
less than 5 x 106 cells. lm L  of Lysis solution was pipetted into one 1.5mL microfuge tube and 
labeled for each sample collected. 10piL 2-mercaptoethanol was mixed thoroughly with the 
lysis solution to promote denaturation of RNases and other proteins. 0.6mL of the lysis buffer 
solution (with 2-mercaptoethanol) was transferred into the respectively labeled 1.5mL 
microfuge tubes containing cell pellets. A sterile pestle was used to grind the cells for 30 
seconds. The homogenate was then transferred to a separate labeled 1.5mL microfuge tube 
using a pipetman. The microfuge tube and pestle were rinsed using one volume (0.6 mL) of 
70% ethanol and added to the cell homogenate using a pipetman. The samples in the 
microfuge tubes were mixed using a labquake for 5 minutes at room temperature to obtain a 
homogeneous mixture.
600pL of the mixture was then transferred into spin cartridges containing a silica resin 
containing a proprietary combination of salts, which selectively binds RNA. The addition of 70%
9
ethanol enhances RNA binding to the silica. Spin cartridges were inserted into collection tubes 
and centrifuged at 12,000 x g for 15 seconds at room temperature. Flow through was discarded 
and the spin cartridge was reinserted into the same collection tube. The remaining 600pL of 
the sample was then transferred into the spin cartridge and it was again centrifuged as 
described before. Once the entire sample had been processed, 600pL of Wash Buffer I 
(proprietary mixture) was added to the spin cartridge to remove proteins and contaminants 
from the silica resin. The spin cartridge was centrifuged at 12,000 x g for 15 seconds at room 
temperature. The flow through was discarded along with the collection tube. The spin 
cartridge was then placed into a new collection tube. 500pL of Wash Buffer II (proprietary 
mixture) containing 100% ethanol was added to spin cartridge to remove remaining salts from  
the silica resin. The spin cartridge was centrifuged at 12,000 x g for 15 seconds at room 
temperature. The flow through was discarded and the spin cartridge was reinserted into the 
same collection tube for one additional wash with 500pL of Wash Buffer II. The samples were 
centrifuged as described before, after which the flow through was discarded and the spin 
cartridges were reinserted into the same collection tubes.
The cartridges were centrifuged for 2 minutes at 12,000 x g to dry the membrane and
remove the remaining ethanol. The flow through and collection tubes were discarded. The
spin cartridges were placed into new collection tubes and centrifuged an additional 2 minutes
at 12,000 x g. Flow through and collection tubes were discarded and the spin cartridges were
inserted into recovery tubes labeled with the date of isolation, cell line, treatment type and
treatment length. 50 pL of RNase-free water (0.05% Diethylpyrocarbonate (DEPC)) was pipetted
directly onto the center of the spin cartridge membrane to rehydrate the silica resin. Samples





















21,000 x g at room temperature to elute RNA from membrane into the recovery tube. Elution 
was repeated once with an additional 50 pL of RNase-free water. A total sample of 100 pL was 
obtained in each recovery tube. Samples were then stored in the -20°F freezer until gel 
electrophoresis was conducted.
Gei Electrophoresis. A 1% Agarose mini Tris-Acetate-EDTA (TAE) gel solution was prepared 
in a graduated bottle containing 96mL of distilled water. 4m L of 25X TAE Buffer (0.04 M Tris 
base, 0.04 M Acetate, 0.001 M EDTA), lg  agarose powder and 30pL ethidium bromide were added 
to the distilled water and swirled gently. The cap was replaced and loosely sealed. The bottle 
was then heated at 30% power in the microwave for approximately 2 minutes while observing 
for first signs of boiling. Once the contents were completely dissolved, the bottle was swirled 
to ensure solubilization of agarose. The contents were allowed to cool slightly in room 
temperature water bath, ensuring that hazing and solidification were not observed. The casting 
tray was prepared and the liquid gel solution was poured slowly into the tray until the solution 
level was approximately halfway from the top of the tape. The comb was then inserted into 
the end of the tray and aligned so that all the wells were centered. The gel was allowed to cool, 
undisturbed, for approximately 30 minutes, until completely solidified.
RNA electrophoresis samples were prepared in 1.5mL microfuge tubes, each containing
lO pL gel loading buffer (GLB) (6% sucrose, 0.1% bromophenol blue) solution. 5pL of each of the
RNA samples were added to the corresponding 1.5mL microfuge tubes and mixed thoroughly
using a pipetman. 5pL of Fermentas O'geneRuler" lk b  Plus DNA Ladder (O.lpg/pL) was added
to a separate 1.5mL microfuge tube containing lO pL GLB. The prepared gel was submerged in
1% TAE buffer solution in the electrophoresis chamber, aligning the wells along the edge of the
plate at the anode of the chamber. 15pL of each of the samples were then carefully loaded into
11
w
a designated lane of the gel using a pipetman. The electrophoresis chamber was then covered
and the electrodes were connected. The voltage was set to 150 Volts delivered continuously 
over the course of 25 minutes. The gel was then removed from the electrophoresis chamber 
for image capture and analysis.
Image Capture and Analysis. The gels were placed into the ultraviolet chamber for image 
capture using Kodak ID  imaging software. Three separate image files were obtained under the 
UV light source. The first image captured was standard UV image without saturation, saved as
Figure 1: First U251 RNA Electrophoresis Gel #2040
From Left:
Lane 1: 5pL 3d -CIS/-RAD U251 RNA; 15.44 ng RNA/pL
Lane 2; 5pL 3d +CIS/-RAD U251 RNA; 25.65 ng RNA/pL
Lane 3; 5pL 3d +CIS/+RAD U251 RNA; 5.45 ng RNA/pL
Lane 4: 5pL 7d -CIS/-RAD U251 RNA; 10.64 ng RNA/pL
Lane 5; 5pL 76 +CIS/-RAD U251 RNA; 4.44 ng RNA/pL
Lane 6: 5pL 76 +CIS/+RAD U251 RNA; 2.33 ng RNA/pL
Lane 7: 5pL O’gene 1 kb Plus DNA Ruler; 80 ng RNA/0.5pg
a bitmap (.bip) file. The second was the 
same captured image exported to a tagged 
image file format (.tif). Finally, the third 
image collected contained saturation levels, 
obtained using the software and was saved 
as a separate bitmap (.bip) file.
Analysis of the images was performed 
using the Kodak ID  imaging software. 
Images were uploaded into the software and 
were straightened and aligned. The bands 
were correlated to the individual lanes of 
the gel using imaging software. The bands 
surrounding the 1.5kb RNA band from the 
DNA ladder were selected to determine net
12
Fiaure 2: Second U251 RNA ElectroDhoresis Gel #2041
From Left:
Lane 1: 5|jL 3d -CIS/-RAD U251 RNA; 7.41 ng RNA/pL 
Lane 2: 5pL 3d +CIS/-RAD U251 RNA; 20.02 ng RNA/pL 
Lane 3: 5pL 3d +CIS/+RAD U251 RNA; 6.05 ng RNA/pL 
Lane 4: 5pL 7d -CIS/-RAD U251 RNA; 4.22 ng RNA/|jL 
Lane 5: 5pL 7d +CIS/-RAD U251 RNA; 19.47 ng RNA/pL 
Lane 6: 5pL 7d +CIS/+RAD U251 RNA; 2.28 ng RNA/pL 
Lane 7: 5pL O’gene 1 kb Plus DNA Ruler; 80 ng RNA/0.5pg
Figure 3: U87 RNA Electrophoresis Gel #2043
From Left:
Lane 1: 5pL 3d -CIS/-RAD U87 RNA; 14.53 ng RNA/pL
Lane 2: 5pL 3d +CIS/-RAD U87 RNA; 6.78 ng RNA/pL
Lane 3: 5pL 3 d +CIS/+RAD U87 RNA; 25.12 ng RNA/pL
Lane 4: 5pL 7d -CIS/-RAD U87 RNA; 25.57 ng RNA/pL
Lane 5: 5pL 7d +CIS/-RAD U87 RNA; 5.96 ng RNA/pL
Lane 6: 5pL 7d +CIS/+RAD U87 RNA; 3.00 ng RNA/pL
Lane 7: 5pL O'gene 1 kb Plus DNA Ruler; 80 ng RNA/0.5pg
intensities. The software determined the net intensities for each of the bands above and below 
the 1.5kb RNA band standard. The net intensities were recorded for the bands in individual 
lanes. The net intensity of the 1.5kb RNA band of the O'gene Plus lkb DNA Ruler was also 
obtained and used as the standard. According to Fermentas' O'Gene lkb Plus Ruler the 1.5kb 
band of the ruler contains 80ng RNA/0.5pg (O.lpg/lpL). Analysis of RNA content (ng RNA/pL) 
for each of the samples was calculated by adding both net intensities for each lane, dividing by 
the net intensity of the 1.5kb band of the DNA ruler, multiplying by the amount of DNA at the 
1.5kb band of the DNA ruler (e.g. 80ng) and finally the dividing by the amount of the RNA 
sample present in each of the lane wells (e.g. 5pL).
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Sample calculation: Gel 2041 Lane 1 20120220 3d U87 RNA -CIS/-RAD
The net intensities of the bands located above and below the 1.5kb standard of the DNA 
ruler were added together: 112445 + 195599 = 308044. The sum of the net intensities of each 
lane was divided by the net intensity of the 1.5kb band in lane 7: 308044 * 145266 = 2.12. The 
result was multiplied by 80ng RNA per microliter and divided by the number of microliters of 
sample used: 2.12 x 80ng RNA * 5|iL = 33.93 ng RNA per microliter.
Table 3: U87 Electrophoresis Gel #2043 Analysis Data
Lane Contents Net Intensities Concentration(ng/uL)
1 5pL 20120220 U87 RNA 3d -CIS -RAD 112445,195599 33.93
2 5pL 20120220 U87 RNA 3d +CIS -RAD 50434,11118 6.78
3 5|iL 20120220 U87 RNA 3d +CIS +RAD 195259, 32815 25.12
4 5pL 20120220 U87 RNA 7d -CIS -RAD 202113,30022 25.57
5 5pL 20120220 U87 RNA 7d +CIS -RAD 43058,11060 5.96
6 5pL 20120220 U87 RNA 7d +CIS +RAD 21203, 6052 3.00
7 5|i.L O'gene 1.5kb plus DNA Ruler 145266 80
Table 4: U251 Electrophoresis Gels #2040 & #2041 Analysis Data












1 5pL U251 RNA 3d -CIS -RAD 82896, 38380 15.44 14907, 34891 7.41 11.43
2 5|iL U251 RNA 3d +CIS -RAD 144956, 56476 25.65 70033, 64578 20.02 22.84
3 5pL U251 RNA 3d +CIS +RAD 24674,18142 5.45 13424, 27210 6.05 5.75
4 5pL U251 RNA 7d -CIS -RAD 53255, 30346 10.64 7605, 20758 4.22 7.43
5 5pL U251 RNA 7d +CIS -RAD 25871, 9010 4.44 70875, 59951 19.47 11.96
6 5pL U251 RNA 7d +CIS +RAD 10837, 7496 2.33 2902,12427 2.28 2.31
7 5|iL O'gene 1.5kb plus DNA Ruler 125658 80 107531 80 80
wV ^ l
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DNase Treatment The RNA isolates were subjected to DNase treatments in order to 
remove any remaining double stranded DNA from the samples prior to cDNA synthesis and 
qPCR analysis. Reactions were performed in 0.2mL PCR vials and required 9\iL of RQ1 DNase 
lOx Reaction Buffer (Promega M198A), l|il_ of RQ1 RNase-free DNase Enzyme (Promega 
M610A) and 10|iL of RQ1 Stop Solution, added after incubation (Promega M199A). 80pL of 
RNA isolate were added for a total of lOOpL per sample reaction. Tables 5 and 6 show the 


































1 20120220 U87 RNA 3d -CIS -RAD 33.93 80 2714.4 9 1 10 100
2 20120220 U87 RNA 3d +CIS -RAD 6.78 80 542.4 9 1 10 100
3 20120220 U87 RNA 3d +CIS +RAD 25.12 80 2009.6 9 1 10 100
4 20120220 U87 RNA 7d -CIS -RAD 25.57 80 2045.6 9 1 10 100
5 20120220 U87 RNA 7d +CIS -RAD 5.96 80 476.8 9 1 10 100
6 20120220 U87 RNA 7d +CIS +RAD 3.00 80 240.0 9 1 10 100























1 20120123 U251 RNA 3d -CIS -RAD 11.43 80 914.4 9 1 10 100
2 20120123 U251 RNA 3d +CIS -RAD 22.84 80 1827.2 9 1 10 100
3 20120123 U251 RNA 3d +CIS +RAD 5.75 80 460.0 9 1 10 100
4 20120123 U251 RNA 7d -CIS -RAD 7.43 80 594.4 9 1 10 100
5 20120123 U251 RNA 7d +CIS -RAD 11.96 80 956.8 9 1 10 100





























The contents of each vial were added in the following order: 80pL RNA sample, 9|iL RQ1 
DNase lOx Reaction Buffer and lp L  RQ1 RNase-free DNase Enzyme. The vials were placed into 
the thermocycler and incubated at B7°C for 2 hours. After the incubation 10pL RQ1 DNase Stop 
Solution were added, bringing the total contents of each vial to lOOpL. The vials were returned 
to the thermocycler for a 10 minute incubation at 65°C to inactivate the DNase enzymes. 
Following the incubation, the vials were centrifuged at 21,000 times gravity for approximately 
10 seconds. The entire contents (lOOpL) of each vial were transferred using a pipetman into 
1.5mL microfuge tubes labeled with the date, treatment length and type, cell line and 
corresponding tube number (e.g. 20120227 U251 3d +/- DNase 2). lO pL 3M sodium acetate 
from prepared stock was added to each vial, creating a 0.3M sodium acetate concentration in 
solution. Two volumes (220pL) of 95% ethanol were added to each tube and mixed gently. The 
tubes were placed into the -20°C freezer overnight for precipitation. After overnight 
precipitation, the tubes were warmed to 37°C and centrifuged for 15 minutes at 21,000 times 
gravity to pellet. The supernatant was carefully decanted, ensuring the pellet remained in the 
microfuge tubes. The microfuge tubes containing the pellets were inverted, allowing any 
excess supernatant to be removed and dried. The pellets were resuspended and washed in 
0.5m L 70% ethanol on the vortex for several seconds, then repelleted by centrifugation at 
21,000 times gravity for 5 minutes. Supernatant was again carefully decanted, ensuring the 
pellets remained in the microfuge tubes, which were inverted again for several minutes to dry. 
The tubes were then placed into the Savant Speed Vac (Model SC110, Serial 191117) for 10 
minutes or until completely dried. Pellets were resuspended in 12pL DEP treated water and 
vortexed for several seconds, then stored in the -20°C freezer until cDNA synthesis and -R T  




















cOAM Synthesis Reactions. The DNase treated RNA samples were removed from the -20°C  
freezer and warmed to 37°C. For each cell line 8pL of each DNase sample were transferred into 
corresponding 0.2mL PCR tubes labeled 1, 2, 3; 4, 5 or 6. One microliter of Oligonucleotide 
09413 decamer, 2pL of a lOOx dilution of 061511 RNA3 from stock and 2.5pL of DEP treated 
water were added to each PCR vial for a total solution volume of 13.5pL. The PCR tubes were 
placed into the thermocycler for 5 minutes at 70°C. The PCR tubes were placed on ice 
immediately after the incubation period. While incubating, the common components for each 
of the reactions plus one additional aliquot were combined. Common components included 
0.5pL per reaction of RNAsin (Promega), 5pL per reaction of 2.5mM dNTPs (Takara Bio Inc.) and 
5pL per reaction of 5x Reaction Buffer (Promega). The common components were gently mixed 
and 10.5pL were pipetted into each of the labeled 0.2m L PCR tubes. One microliter (200u/pL) 
of Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega) was added to 
each PCR tube and gently mixed. Each tube containing a volume of 25|iL mixture was placed 
into the thermocycler and run using the program "cdnapromega42", an automated incubation 
cycle, which incubated the samples at 42°C for 1 hour, 95°C for 5 minutes and then holds the 
samples at 10°C until the cDNA could be diluted and frozen. The entire 25pL of cDNA from each 
of the PCR tubes were transferred into corresponding 1.5mL microfuge tubes. 225pL of DEP 
treated water were added to each of the microfuge tubes, producing a lOx dilution. Tubes 
were labeled with dilution factor, date, cell line, treatment length and type and cDNA reaction 
number, (e.g. lOx Diln 20120301 U251 3d +/- cDNA 2) and stored in -20°C freezer until the 






Negative Reverse Transcriptase Control. A negative reverse transcriptase (RT) control was 
prepared from each of the DNase samples. The purpose of the negative RT control is to 
determine if any contaminating genomic DNA is present after the DNase treatments were 
conducted. The negative RT controls should show high Ct values when run in qPCR compared 
to the Ct values of the cDNA obtained from the reverse transcriptase reactions.
To determine the dilution factor required for the negative RT controls, the overall dilution 
factor with respect to the 10X cDNA was calculated. The 25pL cDNA solution contained 8 pL of 
DNase treated RNA, creating an original dilution of 3.125:1 (25 pL/8 pL), which was further 
diluted 10 times by the addition of 225 pL of DEP treated water. The total cDNA dilution factor 
was 31.25 pL of solution per 1 pL of DNase treated RNA added. In order to standardize the 
negative RT controls to this dilution factor, 2 pL of DNase treated RNA was added to labeled 
1.5mL microfuge tubes for each of the treatments from both cell lines. To obtain the 31.25:1 
dilution, 62.50 pL of solution were required for each reaction. Each tube already contained 2 
pL of RNA and with the addition of 60.50 pL of DEP water, a dilution of 31.25:1 was obtained. 
The tubes were labeled 31.25X Diluition, date, cell line and corresponding treatment type. The 
negative RT controls were stored in the -20°C freezer until the positive control PCR reactions 
were run.
Quantitative Real-Time PCR.
Positive Control Reactions. Positive control reactions were conducted using cDNA and
negative reverse transcription DNase controls and served multiple purposes. First, reactions
having undergone reverse transcription successfully will have produced cDNA, detectable by
PCR in relatively fewer cycles than a negative control. Second, the negative control reactions
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were also successful In denaturing any double stranded contaminating genomic DNA that 
would produce false PCR results.
The positive PCR reactions utilized a primer mixture (Yasui Mix A) containing designated 
primers 07564 and 07565, specific to 18S rRNA sequences. Two 0.2m L PCR tubes were used for 
each treatment type, one for cDNA and the other for the negative RT control. A total of 24 
reactions were conducted with the reaction setups and results listed in tables 7 and 8 below. 
The inclusion of 12.5pL of SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich #S4438) was 
used for quantification during qPCR and contained the heat stable Taq (Thermus aquaticus) 
polymerase (0.05 units/pL).











Sample Contents (Cisplatin/Gamma) (pL) SYBR (|xL) Ct (dRn)
121257 9.5 3|iL 2012030110X dilution U251 cDNA 13d (-/-) 12.5 18.07
121258 9.5 3pL 20120301 31.25X dilution U251 Dnase 1 3d (-/-) 12.5 NoCt
121259 9.5 3|iL 2012030110X dilution U251 cDNA 2 3d (+/-) 12.5 17.37
121260 9.5 3pL 2012030131.25X dilution U251 Dnase 2 3d (+/-) 12.5 38.5
121261 9.5 3pL 2012030110X dilution U251 cDNA 3 3d (+/+) 12.5 18.7
121262 9.5 3pL 2012030131.25X dilution U251 DNase 3 3d (+/+) 12.5 No Ct
121263 9.5 3pL 2012030110X dilution U251 cDNA 4 7d (-/-) 12.5 15.74
121264 9.5 3pL 2012030131.25X dilution U251 Dnase 4 7d (-/-) 12.5 No Ct
121265 9.5 3pL 2012030110X dilution U251 cDNA 5 7d (+/-) 12.5 17.27
121266 9.5 3pL 2012030131.25X dilution U251 Dnase 5 7d (+/-) 12.5 NoCt
121267 9.5 3pL 2012030110X dilution U251 cDNA 6 7d (+/+) 12.5 20.46
121268 9.5 3pL 2012030131.25X dilution U251 DNase 6 7d (+/+) 12.5 No Ct
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Sample Contents (Cisplatin/Gamma) (pL) SYBR (pL) Ct (dRn)
121861 9.5 3pL 20120316 10X dilution U87 cDNA 1 3d (-/-) 12.5 15.68
121862 9.5 3pL 20120316 31.25X dilution U87 Dnase 13d (-/-) 12.5 38.91
121863 9.5 3pL 20120316 10X dilution U87 cDNA 2 3d (+/-) 12.5 15.06
121864 9.5 3pL 20120316 31.25X dilution U87 Dnase 2 3d (+/-) 12.5 38.67
121865 9.5 3pL 20120316 10X dilution U87 cDNA 3 3d (+/+) 12.5 11.41
121866 9.5 3pl 20120316 31.25X dilution U87 DNase 3 3d (+/+) 12.5 NoCt
121867 9.5 3[iL 2012031610X dilution U87 cDNA 4 7d (-/-) 12.5 13.52
121868 9.5 3|iL 20120316 31.25X dilution U87 Dnase 4 7d (-/-) 12.5 NoCt
121869 9.5 3|il 2012031610X dilution U87 cDNA 5 7d (+/-) 12.5 18.93
121870 9.5 3pL 20120316 31.25X dilution U87 Dnase 5 7d (+/-) 12.5 38.70
121871 9.5 3|il 2012031610X dilution U87 cDNA 6 7d (+/+) 12.5 19.42
121872 9.5 3pL 20120316 31.25X dilution U87 DNase 6 7d (+/+) 12.5 38.42
The contents were added in the order of primer mixture, cDNA or RNA sample and then 
SYBR Green. The tubes were centrifuged at 1000 times gravity for 10 seconds, vortexed for 10 
seconds to mix thoroughly and centrifuged again at 1000 times gravity for 10 seconds. The PCR 
tubes were loaded into the PCR thermocycler and run for 40 cycles. Each cycle consisted of a 
95°C dissociation for 30 seconds, a 60°C annealing phase for 30 seconds and a 72°C extension 
phase for 60 seconds, with a final extension of 60 seconds and a temperature hold of 4°C until 
stored in the -20°C freezer.
Apoptosis Arrays. In order to identify the effects of cisplatin and combination cisplatin and 
gamma irradiation treatments on the genes associated with apoptosis in U87 and U251 GBM 
cell lines, Human RT2 Apoptosis Arrays (Qiagen PAHS-012A) were used. The arrays contained 


















wells contained primers specific to apoptosis related genes, while the other 12 wells contained 
primer sequences for housekeeping genes, positive PCR reactions and reverse transcription 
controls.
The apoptosis arrays were stored in the -20°C freezer until the reactions were to be 
conducted to ensure stability of the primers. Upon use, the array was brought to room 
temperature, centrifuged, unopened, at 1000 times gravity for 15 seconds. The core 
components for the reaction setup were added together into two separate 1.5mL microfuge 
tubes each containing enough for 55 (25pL) reactions. The common components per tube 
included 572pL (10.43pL/reaction) of DEP water, 692pL (12.5|iL/reaction) of SYBR Green 
JumpStart Taq ReadyMix (Sigma-Aldrich #S4438), lOOpL (1.82pL/reaction) of cDNA sample from  
one of the treatment types of a given cell line and 13.75pL (0.25pL/reaction) of R4526 
Reference Dye (Sigma-Aldrich). Each well of the array received a total of 25pL of the core 
mixture. After filling each column of eight wells in the array a strip tube cover was placed atop 
of the wells to avoid contamination. Half of the arrays (48 wells) were prepared using one of 
the core component mixtures, and the second mixture was used to prepare the second halves 
of the arrays. Once loaded, the arrays were centrifuged at 1000 times gravity for 15 seconds, 
vortexed for 15 seconds to mix and centrifuged again. The arrays were loaded into the qPCR 
thermocycler and underwent 40 cycles of 95°C dissociations for 30 seconds, a 60°C annealing 
phases for 30 seconds and a 72°C extension phases for 60 seconds, with a final extensions of 60 












Positive Control PCR Reactions
The purpose of this experiment was to determine the effectiveness of the reverse 
transcriptase in preparation of the cDNA samples from the DNase treated RNA samples. The 
31.25x dilutions of the DNase treated RNAs were used as negative reverse transcription 
controls in order to determine if any contaminating genomic DNA was present after treatments 
with DNase. The cDNA samples showed much lower threshold (Ct) values than the DNase RNA 
samples, indicating that there was successful reverse transcription of the mRNA isolated from  
the U87 and U251 cells. The negative reverse transcription controls showed much higher 
threshold values due to lower concentrations of the desired template, present only as 
contaminating genomic DNA. For actual threshold (Ct) values, see tables 7 and 8 above.
Apoptosis Array PCR Reactions
w  Six apoptosis arrays were conducted for each cell lineage. Two arrays for cisplatin only
w
treatment, two for cisplatin and gamma irradiation concurrent treatment and two for
w
w  untreated controls. Each of the arrays from the treatment groups corresponded to either three
w








Tables 9 and 10 provide the fold regulations for each of the treatment types compared 
to the untreated controls at either three or seven days. The data includes the 84 apoptosis 
related genes and 5 housekeeping genes used for standardization. Genes appearing in red 
indicate pro-apoptotic genes and those appearing in black represent anti-apoptotic genes. 
Wells H1-H5 consist of the housekeeping genes and have no bearing on regulation of apoptosis
22
win the cells. Figures 4-11 depict graphical representations of the fold value regulations 





















Analysis of the results provided no definitive conclusions on whether or not treatment 
with cisplatin alone or concurrent treatment with cisplatin and gamma irradiation had any 
effect on the regulation of apoptosis. There are several intricate cellular pathways that require 
regulation at multiple steps allowing for apoptosis to proceed. Here we focused on five pro- 
apoptotic genes specific to the DNA damage pathway leading to apoptosis. The five genes, 
ABL1, CIDEA, CIDEB, TP53 and TP73, were found to have undergone slight (under three-fold) up 
and down regulation. U251 cells showed over a 4.5 fold increase in CIDEA at the seven day 
treatment length with cisplatin and gamma irradiation. U87 cells showed significant gene 
regulation differences in the TP53 and TP73 tumor suppressor genes. In both treatments for 
the seven day treatment period, the TP53 gene was down regulated nearly 3.5 fold. TP53 is an 
essential pro-apoptotic tumor suppressor protein and its down regulation is may indicate that 
cell death is occurring in a manner other than apoptosis, through either necrosis or autophagy. 
TP73, a tumor suppressor protein belonging to the TP53 family of tumor suppressor proteins, 
was initially down regulated approximately 5.5 fold in the U87 three day combination 
treatment. However, both U87 seven day treatments show significant up regulation of the 
TP73 gene. There was approximately a fifty fold increase in the expression levels of TP73 in
these cells. Over expression of TP73 in medullablastoma tumors has been shown to increase
23
w
levels of apoptotic cell death in similar studies (Castellino et al., 2007). Continued analysis into 
the expression levels of the other genes associated with apoptosis pathways may provide more
insight into the mechanisms of cell death that the cells underwent as a result of the treatments.






Pro  (+) or 
A nti (-) 
A po ptotic
U 2 5 1 3
Day
+Cisp latin  
-G am m a  
vs 3  Day  
Control
U 2 5 1 3
Day
+Cisplatin  
+Gam m a  
vs 3 Day  
Control
U 2 5 1 7
D ay
+Cisplatin  
-Gam m a  
vs 7 Day  
Control
U 2 5 1 7
D ay
+Cisp latin  
+G am m a  
vs 7  Day  
Control
A 1 A B L 1 C - a b l  o n c o g e n e  1 , n o n - r e c e p t o r  t y r o s i n e  k in a s e + - 1 . 2 8 - 1 . 5 1 1 .5 5 1 .2 7
A 2 A K T 1 V - a k t  m u r in e  t h y m o m a  v ir a l  o n c o g e n e  h o m o lo g  1 - - 1 . 3 0 - 1 . 3 4 - 1 . 9 9 - 1 . 1 3
A 3 A P A F 1 A p o p t o t i c  p e p t id a s e  a c t i v a t i n g  f a c t o r  1 + - 1 . 0 7 - 1 . 0 7 1 .2 9 - 1 . 0 9
A 4 B A D B C L 2 - a s s o c i a t e d  a g o n i s t  o f  c e l l  d e a t h + - 1 . 1 8 1 .8 6 - 1 . 0 4 - 1 . 2 8
A S B A G 1 B C L 2 - a s s o c i a t e d  a t h a n o g e n e - - 1 . 7 1 - 1 . 4 9 1 .3 0 1 .6 4
A 6 B A G 3 B C L 2 - a s s o c i a t e d  a t h a n o g e n e  3 - - 1 . 1 7 - 7 . 2 2 1 .0 2 1 .4 1
A 7 B A G 4 B C L 2 - a s s o c i a t e d  a t h a n o g e n e  4 - 1 .1 7 1 . 2 0 1 .1 7 1 .3 7
A 8 B A K 1 B C L 2 - a n t a g o n i s t / k i l l e r  1 + 1 .0 1 1 .2 4 2 .4 6 2 .1 7
A 9 B A X B C L 2 - a s s o c i a t e d  X  p r o t e in + - 1 . 3 8 - 1 . 0 1 - 1 . 2 4 1 .1 3
A 1 0 B C L 1 0 B - c e l l  C L L / l y m p h o m a  1 0 + 1 .2 7 2 .1 5 - 1 . 0 2 1 .6 8
A l l B C L 2 B - c e l l  C L L / l y m p h o m a  2 - 1 .9 2 - 3 . 4 9 - 1 . 0 5 1 3 . 8 3
A 1 2 B C L 2 A 1 B C L 2 - r e la t e d  p r o t e in  A 1 - 2 .8 4 5 .9 3 1 .0 9 1 .6 9
B 1 B C L 2 L 1 B C L 2 - l i k e  1 - 1 .0 9 1 .2 5 - 2 . 2 0 1 .2 7
B 2 B C L 2 L 1 0 B C L 2 - l i k e  1 0  ( a p o p t o s i s  f a c i l i t a t o r ) - - 2 . 4 7 1 .0 1 2 . 3 0 4 . 6 9
B 3 B C L 2 L 1 1 B C L 2 - l i k e  1 1  ( a p o p t o s i s  f a c i l i t a t o r )
+ 1 .8 6 6 .4 0 - 2 . 3 9 - 1 . 4 9
B 4 B C L 2 L 2 B C L 2 - l i k e  2 - 1 .2 2 1 .1 2 1 .8 8 2 .1 0
B 5 B C L A F 1 B C L 2 - a s s o c i a t e d  t r a n s c r i p t i o n  f a c t o r  1 + - 1 . 0 0 - 1 . 7 1 1 .1 6 - 1 . 3 0
B 6 B F A R B i f u n c t io n a l  a p o p t o s i s  r e g u la t o r - - 1 . 3 0 - 1 . 5 4 1 .7 2 1 .7 4
B 7 B ID B H 3  in t e r a c t i n g  d o m a in  d e a t h  a g o n i s t + - 1 . 1 4 1 .4 5 - 1 . 0 2 2 .6 8
B 8 B IK B C L 2 - i n t e r a c t i n g  k i l le r  ( a p o p t o s i s  i n d u c in g ) + - 2 . 4 7 1 .0 1 2 .2 3 5 . 8 6
B 9 N A I P N R L  f a m i ly ,  a p o p t o s i s  i n h i b i t o r y  p r o t e in - 1 .2 0 - 1 . 1 2 2 .9 9 2 .6 9
B I O B I R C 2 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  2 + 1 .4 5 1 .4 1 1 . 3 0 1 .9 7
B l l B I R C 3 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  3 - 6 .6 2 2 5 . 4 1 - 2 . 9 1 1 0 . 2 7
B 1 2 X IA P X - l i n k e d  in h ib i t o r  o f  a p o p t o s i s - 3 .7 0 1 .0 3 - 5 . 4 3 - 1 . 6 7
C l B I R C 6 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  6 - 1 .2 5 2 .3 4 1 .2 3 1 .3 9
C 2 B I R C 8 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  8 - - 3 . 4 4 - 1 . 3 9 2 . 3 0 7 .3 1
C 3 B N IP 1 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  in t e r a c t i n g  p r o t e in  1
+ - 1 . 2 4 1 .7 0 1 .1 1 - 1 . 0 5
C 4 B N IP 2 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  in t e r a c t i n g  p r o t e in  2 - 1 .0 6 - 1 . 1 7 1 .4 3 1 .4 5
C 5 B N IP 3 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  i n t e r a c t i n g  p r o t e in  3 + 1 .0 1 1 .4 5 1 .4 9 1 .2 7
C 6 B N I P 3 L B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  i n t e r a c t i n g  p r o t e in  3 - l i k e + - 1 . 2 8 - 1 . 2 9 4 . 2 6 2 .3 3
C 7 B R A F V - r a f  m u r in e  s a r c o m a  v ir a l  o n c o g e n e  h o m o lo g  B 1 - 1 .2 1 1 .2 7 1 . 5 8 1 .4 3
C 8 N O D I N u c l e o t i d e - b i n d i n g  o l ig o m e r i z a t i o n  d o m a i n  c o n t a i n i n g  1
+ 1 .0 8 1 .9 2 1 .6 1 1 .3 9
C 9 C A R D 6 C a s p a s e  r e c r u i t m e n t  d o m a in  f a m i l y ,  m e m b e r  6 + - 1 . 7 7 1 .2 8 1 .4 0 1 .6 4
C I O C A R D 8 C a s p a s e  r e c r u i t m e n t  d o m a in  f a m i l y ,  m e m b e r  8 + - 1 . 5 1 - 8 . 6 5 - 1 . 4 9 - 1 . 0 9
C l l C A S P 1 C a p a s e  1 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 0 5 1 .4 1 2 .5 1 1 .3 2
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Table 9: U251 PCR Fold Regulations (Cont.)





Gene D iscrip tion
Pro  (+ ) or 




-G am m a  




+G am m a  




-G am m a  





vs 7 Day  
Control
C 1 2 C A S P 1 0 C a s p a s e  1 0 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 2 . 0 2 1 .0 1 2 .3 0 4 . 6 9
D 1 C A S P 1 4 C a s p a s e  1 4 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 7 6 - 1 . 4 5 - 2 . 7 5 3 . 7 1
D 2 C A S P 2 C a s p a s e  2  , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 2 8 - 1 . 0 4 1 .0 5 - 1 . 5 8
D 3 C A S P 3 C a s p a s e  3  , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ 1 .1 8 1 .2 5 - 1 . 1 3 - 1 . 4 0
D 4 C A S P 4 C a s p a s e  4 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 3 0 - 1 . 0 2 2 .5 5 2 .7 7
D 5 C A S P 5 C a s p a s e  5 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 2 . 4 7 1 .0 1 2 .3 0 4 . 6 9
D 6 C A S P 6 C a s p a s e  6 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 5 4 - 1 . 5 0 2 .6 2 - 1 . 2 7
D 7 C A S P 7 C a s p a s e  7 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 2 2 1 .2 6 2 .0 3 1 .0 6
D 8 C A S P 8 C a s p a s e  8 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ 1 .0 4 1 .4 9 1 .3 0 1 .6 2
D 9 C A S P 9 C a s p a s e  9  , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 1 7 1 .1 7 2 .6 8 2 .7 9
D I O C D 4 0 C D 4 0  m o le c u le ,  T N F  r e c e p t o r  s u p e r f a m i l y  m e m b e r  5
+ - 2 . 4 7 1 .0 1 2 .3 0 4 . 6 9
D l l C D 4 0 L G C D 4 0  l ig a n d
+ - 2 . 4 7 1 .3 3 2 .3 0 1 7 . 2 7
D 1 2 C F L A R C A S P 8  a n d  F A D D - l i k e  a p o p t o s i s  r e g u la t o r - - 1 . 3 8 1 .3 7
1 .3 9 1 .0 7
E l C I D E A C e l l  d e a t h - i n d u c i n g  D F F A - l i k e  e f f e c t o r  a
+ - 2 . 4 7 1 .0 1 2 .3 0 4 . 6 9
E 2 C I D E B C e l l  d e a t h - i n d u c i n g  D F F A - l i k e  e f f e c t o r  b
+ - 1 . 9 2 - 1 . 0 7 - 1 . 0 4 1 .1 8
E 3 C R A D D
C A S P 2  a n d  R I P K 1  d o m a in  c o n t a i n i n g  a d a p t o r  w i t h  d e a t h  
d o m a in
+ 1 .0 2 1 .7 7 1 .3 1 1 .0 2
E 4 D A P K 1 D e a t h - a s s o c ia t e d  p r o t e in  k in a s e  1
+ - 1 . 0 1 1 .6 1 6 .4 1 1 .5 5
E 5 D F F A D N A  f r a g m e n t a t i o n  f a c t o r ,  4 5 k D a ,  a lp h a  p o l y p e p t i d e
+ - 1 . 3 2 - 1 . 5 2 1 .8 7 1 .4 9
E 6 F A D D F a s  ( T N F R S F 6 ) - a s s o c ia t e d  v ia  d e a t h  d o m a in
+ 1 .0 5 1 .5 0 - 1 . 4 9 - 1 . 0 6
E 7 F A S F a s  ( T N F  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  6 )
+ 1 .2 0 1 .3 1 1 .3 6 1 .9 2
E 8 F A S L G F a s  l i g a n d  ( T N F  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  6 )
+ - 2 . 4 7 1 .5 9 2 . 3 0 4 . 6 9
E 9 G A D D 4 5 A G r o w t h  a r r e s t  a n d  D N A - d a m a g e - i n d u c i b l e ,  a lp h a
+ 2 . 5 6 2 5 . 9 5 - 5 . 3 1 6 . 2 8
E 1 0 H R K H a r a k i r i ,  B C L 2  i n t e r a c t i n g  p r o t e in  ( c o n t a i n s  o n l y  B H 3  d o m a in )
+ - 2 . 2 1 9 . 3 7 - 1 . 1 0 1 9 . 7 0
E l l IG F 1 R I n s u l in - l i k e  g r o w t h  f a c t o r  1  r e c e p t o r - 1 .5 6 2 . 0 7
- 1 . 2 6 - 1 . 4 3
E 1 2 L T A L y m p h o t o x in  a lp h a  ( T N F  s u p e r f a m i l y ,  m e m b e r  1 )
+ - 1 . 7 4 1 .7 1 1 .2 9 4 . 2 0
F I L T B R L y m p h o t o x in  b e t a  r e c e p t o r  ( T N F R  s u p e r f a m i l y ,  m e m b e r  3 )
+ - 1 . 2 2 1 .2 2 1 .5 7 1 . 6 0
F 2 M C L 1 M y e lo id  c e l l  l e u k e m ia  s e q u e n c e  1  ( B C L - r e l a t e d ) -
1 .1 2 2 . 7 8 - 1 . 2 9 - 1 . 1 1
F 3 N O L 3 N u c le o la r  p r o t e in  3  ( a p o p t o s i s  r e p r e s s o r  w it h  C A R D  d o m a in ) - - 1 . 4 3
- 1 . 2 4 8 . 6 3 5 . 7 0
F 4 P Y C A R D P Y D  a n d  C A R D  d o m a in  c o n t a i n i n g
+ - 1 . 8 4 1 .9 4 4 . 6 6 2 3 . 1 0
F 5 R IP K 2 R e c e p t o r - i n t e r a c t i n g  s e r i n e - t h r e o n in e  k in a s e  2 -
1 .3 1 1 .6 6 1 .0 4 2 . 7 3
F 6 T N F T u m o r  n e c r o s i s  f a c t o r
+ - 3 . 2 3 1 .3 0 2 .3 0 5 1 . 9 8
F 7
T N F R S F 1 0
A T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 0 a
+ - 2 . 4 7 1 .0 1 2 .3 0 4 . 6 9
F 8
T N F R S F 1 0
B T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 0 b
+ 1 .4 9 2 .0 0 1 .4 2 1 .7 1
F 9
T N F R S F 1 1
B T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  l i b
+ - 2 . 4 7 1 .6 8 2 .3 0 9 . 0 0
F 1 0 T N F R S F 1 A T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 A
+ - 1 . 3 3 1 .3 8 - 5 6 . 4 9 - 1 . 3 9
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G ene D iscrip tion
Pro  (+) o r  
Anti (-) 
A po p to tic
U 2 5 1 3
D ay
-rCisplatin  
-G am m a  
vs 3 D ay  
Control
U 2 5 1 3
Day
+Cisplatin  
+G am m a  
vs 3 Day  
Control
U 2 5 1 7
D ay
-rCisplatin  
-G am m a  
vs 7 Day  
Control




vs 7  D ay  
Control
F l l T N F R S F 2 1 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  2 1
+ - 1 . 0 1 - 1 . 6 6 1 .6 8 1 .8 0
F 1 2 T N F R S F 2 5 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  2 5
+ 1 .4 5 2 .7 3 2 .4 3 2 .4 1
G 1 C D 2 7 C D 2 7  m o le c u le - - 1 . 8 3 - 1 . 0 5 1 .7 8 8 . 1 7
G 2 T N F R S F 9 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  9
+ 1 .1 1 1 0 . 9 1 - 4 . 8 2 1 2 . 1 3
G 3 T N F R S F 1 0 T u m o r  n e c r o s i s  f a c t o r  ( l i g a n d )  s u p e r f a m i l y ,  m e m b e r  1 0
+ 2 .0 8 2 .0 2 1 .1 7 3 . 2 5
G 4 C D 7 0 C D 7 0  m o le c u le
+ 1 .1 9 1 .4 1 - 1 . 5 3 - 1 . 3 3
G 5 T N F R S F 8 T u m o r  n e c r o s i s  f a c t o r  ( l i g a n d )  s u p e r f a m i l y ,  m e m b e r  8
+ 4 . 4 6 1 .0 1 2 . 6 4 1 3 . 8 3
G 6 T P S 3 T u m o r  p r o t e in  p 5 3
+ - 1 . 4 0 - 1 . 4 3 1 .6 8 1 .2 7
G 7 T P 5 3 8 P 2 T u m o r  p r o t e in  p 5 3  b in d in g  p r o t e in ,  2
+ - 1 . 0 4 1 .0 8 2 .0 3 1 .5 4
G 8 T P 7 3 T u m o r  p r o t e in  p 7 3
+ - 2 . 1 6 - 1 . 6 8 1 .4 5 2 .7 7
G 9 T R A D D T N F R S F l A - a s s o c i a t e d  v ia  d e a t h  d o m a in
+ - 1 . 1 8 1 .4 4 1 .6 4 1 .7 8
G 1 0 T R A F 2 T N F  r e c e p t o r - a s s o c i a t e d  f a c t o r  2 - - 1 . 0 6 1 .7 9 - 1 . 0 0
1 .4 4
G i l T R A F 3 T N F  r e c e p t o r - a s s o c i a t e d  f a c t o r  3
+ 1 .1 1 1 .6 4 1 .0 1 1 .4 2
G 1 2 T R A F 4 T N F  r e c e p t o r - a s s o c i a t e d  f a c t o r  4 - - 1 . 2 2 1 .1 5 1 .8 3
1 .2 1
H O I B 2 M B e t a - 2  m ic r o g l o b u l i n N / A 1 .3 7 1 .4 0 1 .5 1
2 .3 5
H 0 2 H P R T 1 H y p o x a n t h i n e - g u a n in e  p h o s p h o r i b o s y l t r a n s f e r a s e N / A 1 .2 0 - 1 . 3 8 - 1 . 3 3
1 .0 4
H 0 3 R P L 1 3 A 6 0 S  r ib o s o m a l  p r o t e in  L 1 3 a N / A - 1 . 2 6 1 .2 6 - 1 . 4 1
- 1 . 4 7
H 0 4 G A P D H G l y c e r a l d e h y d e  3 - p h o s p h a t e  d e h y d r o g e n a s e N / A - 1 . 3 1 - 1 . 2 9 1 .2 5
- 1 . 6 5
H 0 5 A C T B B e t a - a c t in
N / A - 1 . 5 1 - 2 . 4 8 1 .6 2 1 .1 7
27






Pro (+) or 
A nti (-) 
A po ptotic
U 8 7 3 D ay  
-fCisplatin  
-G am m a  
vs 3 Day  
Control
U 8 7 3 D ay  
+Cisplatin  
+G am m a  
vs 3 D ay  
Control
U87 7 Day  
-fCisplatin  
-G am m a  
v s 7 D ay  
Control
U87 7 D ay  
-fCisplatin  
+Gam m a  
vs 7 D ay  
Control
A 1 A B L 1 C - a b l  o n c o g e n e  1 , n o n - r e c e p t o r  t y r o s i n e  k in a s e
+ 1 .2 4 1 .3 5 - 2 . 3 4 - 1 . 8 6
A 2 A K T 1 V - a k t  m u r in e  t h y m o m a  v ir a l  o n c o g e n e  h o m o lo g  1 - 1 .0 3 1 .2 1 1 .0 2
- 1 . 0 2
A 3 A P A F 1 A p o p t o t i c  p e p t i d a s e  a c t i v a t i n g  f a c t o r  1
+ 1 .3 6 1 .4 1 - 1 . 7 9 1 .1 1
A 4 B A D B C L 2 - a s s o c i a t e d  a g o n i s t  o f  c e l l  d e a t h
+ - 1 . 1 2 1 .1 3 1 .7 7 1 .6 4
A 5 B A G 1 B C L 2 - a s s o c i a t e d  a t h a n o g e n e - - 1 . 0 2 - 1 . 7 9 - 2 . 6 3
1 . 1 0
A 6 B A G 3 B C L 2 - a s s o c i a t e d  a t h a n o g e n e  3 - 1 .0 9 1 .3 6 - 2 . 9 0
- 2 . 9 2
A 7 B A G 4 B C L 2 - a s s o c i a t e d  a t h a n o g e n e  4 - 1 .2 5 1 .0 3 - 1 . 4 1 - 1 . 1 1
A 8 B A K 1 B C L 2 - a n t a g o n i s t / k i l l e r  1
+ - 2 . 0 7 - 1 . 2 2 - 1 . 1 2 - 1 . 1 1
A 9 B A X B C L 2 - a s s o c i a t e d  X  p r o t e in
+ - 1 . 1 1 - 1 . 4 7 2 .0 7 1 .7 1
A 1 0 B C L 1 0 B - c e l l  C L L / l y m p h o m a  1 0
+ 1 .0 5 1 .2 8 - 1 . 5 3 - 1 . 7 2
A l l B C L 2 B - c e l l  C L L / l y m p h o m a  2 - 6 . 7 3 - 2 . 4 8 4 2 . 3 0 1 3 . 4 1
A 1 2 B C L 2 A 1 B C L 2 - r e la t e d  p r o t e in  A 1 - 1 .2 8 1 .1 6 3 . 2 5 2 1 . 7 8
B 1 B C L 2 L 1 B C L 2 - l i k e  1 - 1 .7 3 1 .5 8 1 .7 6 1 .9 7
B 2 B C L 2 L 1 0 B C L 2 - l i k e  1 0  ( a p o p t o s i s  f a c i l i t a t o r ) - 1 .2 4 1 .2 2 1 2 . 6 6 7 .6 5
B 3 B C L 2 L 1 1 B C L 2 - l i k e  1 1  ( a p o p t o s i s  f a c i l i t a t o r )
+ 1 .8 7 - 1 . 8 8 1 .2 2 4 .6 1
B 4 B C L 2 L 2 B C L 2 - l i k e  2 - 1 .1 3 2 .1 1 - 1 . 9 8 1 .5 1
B 5 B C L A F 1 B C L 2 - a s s o c i a t e d  t r a n s c r i p t i o n  f a c t o r  1
+ 1 .0 8 - 1 . 1 9 - 3 . 3 8 - 2 . 2 4
B 6 B F A R B i f u n c t io n a l  a p o p t o s i s  r e g u la t o r - 1 .0 9 1 .2 1 - 2 . 3 1 - 2 . 0 6
B 7 B ID B H 3  i n t e r a c t i n g  d o m a i n  d e a t h  a g o n i s t
+ 1 .1 3 1 .1 5 - 1 . 3 4 1 .3 6
B 8 B IK B C L 2 - i n t e r a c t i n g  k i l le r  ( a p o p t o s i s  i n d u c in g )
+ - 1 . 7 5 - 1 . 2 1 1 0 . 8 0 6 .5 2
B 9 N A I P N R L  f a m i ly ,  a p o p t o s i s  in h i b i t o r y  p r o t e in - - 1 . 0 1 1 .4 4 - 2 . 9 0 - 1 . 1 3
B I O B I R C 2 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  2
+ 1 .1 6 - 1 . 0 0 - 1 . 1 5 2 . 2 0
B l l B I R C 3 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  3 - 1 .8 3 1 .8 1 1 .0 8
1 .7 4
B 1 2 X I A P X - l in k e d  in h i b i t o r  o f  a p o p t o s i s - 4 .1 1 - 1 . 0 7 4 1 . 4 3 - 1 . 1 9
C l B I R C 6 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  6 - 3 .2 9 - 1 . 4 2
4 . 5 4 3 . 0 6
C 2 B I R C 8 B a c u lo v i r a l  IA P  r e p e a t  c o n t a i n i n g  8 -
- 2 . 0 4 - 1 2 . 1 5 4 4 . 4 0 2 7 . 7 6
C 3 B N IP 1 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  in t e r a c t i n g  p r o t e in  1
+ - 1 . 1 6 - 1 . 2 4 - 1 . 1 7 - 1 . 9 8
C 4 B N IP 2 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  in t e r a c t i n g  p r o t e in  2 - 1 .0 6 1 .1 8 - 1 . 8 2 - 1 . 4 2
C 5 B N IP 3 B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  in t e r a c t i n g  p r o t e in  3
+ 1 .5 1 3 .2 2 1 .0 7 2 .4 2
C 6 B N I P 3 L B C L 2 - a d e n o v i r u s  E 1 B  1 9 k D a  i n t e r a c t i n g  p r o t e in  3 - l i k e
+ 1 .1 5 3 .0 3 - 2 . 5 6 - 1 . 4 4
C 7 B R A F V - r a f  m u r in e  s a r c o m a  v ir a l  o n c o g e n e  h o m o lo g  B 1 - - 1 . 1 2 1 .3 8 - 3 . 4 0 - 2 . 8 2
C 8 N O D I N u c l e o t i d e - b i n d i n g  o l i g o m e r i z a t i o n  d o m a in  c o n t a i n i n g  1 - 1 . 3 1 - 1 . 0 6 - 1 . 2 7 1 .5 3
C 9 C A R D 6 C a s p a s e  r e c r u i t m e n t  d o m a in  f a m i l y ,  m e m b e r  6
+ 1 .4 9 1 .2 2 - 1 . 3 9 1 .0 9
C I O C A R D 8 C a s p a s e  r e c r u i t m e n t  d o m a in  f a m i l y ,  m e m b e r  8
+ 1 .5 2 1 .9 2 - 1 . 8 2 - 3 . 0 2
C l l C A S P 1 C a p a s e  1 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ 1 .1 4 1 .0 8 - 1 . 1 5 - 1 . 1 6
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Table 10: U87 PCR Fold Regulations (Cont.)
U87 3 D ay U87 3  Day U 8 7 7 Day U 8 7 7 Day
Pro (+ )  or +Cisp latin -t-Cisplatin +Cisp latin +Cisplatin
N um ber Sym bol
G ene D iscrip tion A nti (-) 
A po ptotic
-G am m a  
v s 3 D ay
+Gam m a  
v s 3 D ay
-G am m a  
vs 7 Day
+Gam m a  
vs 7 Day
Control Control Control Control
C 1 2 C A S P 1 0 C a s p a s e  1 0 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ 1 .4 6 3 .5 2 - 7 . 0 0 - 1 . 1 9
D 1 C A S P 1 4 C a s p a s e  1 4 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + 1 .3 8 - 1 0 . 8 0 1 8 6 .4 3 4 8 . 6 7
D 2 C A S P 2 C a s p a s e  2 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + - 1 . 0 3 - 1 . 0 3 - 1 . 2 9 - 1 . 7 5
D 3 C A S P 3 C a s p a s e  3 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + 1 .6 1 - 1 . 1 7 1 .1 3 1 .4 6
D 4 C A S P 4 C a s p a s e  4 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 0 2 1 .5 6 - 2 . 0 1 - 1 . 9 1
D 5 C A S P 5 C a s p a s e  5 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + - 1 . 7 5 1 .4 8 6 .6 0 3 . 9 9
D 6 C A S P 6 C a s p a s e  6 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + 1 .0 1 - 1 . 1 1 1 .0 7 - 1 . 8 3
D 7 C A S P 7 C a s p a s e  7 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + - 1 . 0 1 - 1 . 1 7 - 1 . 0 6 1 .1 8
0 8 C A S P 8 C a s p a s e  8 , a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e
+ - 1 . 2 8 1 .0 1 - 1 . 6 4 - 1 . 3 7
D 9 C A S P 9 C a s p a s e  9 ,  a p o p t o s i s - r e l a t e d  c y s t e i n e  p e p t id a s e + - 1 . 1 1 - 1 . 0 0 - 1 . 0 3 - 1 . 0 3
0 1 0 C D 4 0 C D 4 0  m o l e c u l e ,  T N F  r e c e p t o r  s u p e r f a m i l y  m e m b e r  5 + - 1 . 6 9 1 .6 0 - 1 . 0 1 - 1 . 1 4
D l l C D 4 0 L G C D 4 0  l i g a n d + - 1 . 7 5 - 2 . 1 5 6 .4 2 3 .8 8
D 1 2 C F L A R C A S P 8  a n d  F A D D - l i k e  a p o p t o s i s  r e g u l a t o r - - 1 . 0 4 1 .1 6 - 1 . 1 5 1 .6 3
E l C I D E A C e l l  d e a t h - i n d u c i n g  D F F A - l i k e  e f f e c t o r  a + - 2 . 1 9 1 .1 0 - 1 . 6 3 - 2 . 7 0
E 2 C I D E B C e l l  d e a t h - i n d u c i n g  D F F A - l i k e  e f f e c t o r  b + - 1 . 0 9 - 1 . 1 1 - 1 . 9 3 1 .7 6
E 3 C R A D D
C A S P 2  a n d  R I P K 1  d o m a in  c o n t a i n i n g  a d a p t o r  w i t h  d e a t h  
d o m a in
+ 1 .1 2 - 1 . 5 7 1 .2 8 1 .8 3
E 4 D A P K 1 D e a t h - a s s o c ia t e d  p r o t e in  k in a s e  1 + 2 .4 5 1 .3 4 2 1 . 0 0 3 6 . 8 9
E 5 D F F A D N A  f r a g m e n t a t i o n  f a c t o r ,  4 5 k D a ,  a lp h a  p o l y p e p t i d e + - 1 . 0 6 1 .6 6 - 3 . 6 0 - 3 . 7 7
E 6 F A D D F a s  ( T N F R S F 6 ) - a s s o c ia t e d  v ia  d e a t h  d o m a in
+ 1 .1 0 - 1 . 7 0 2 .2 5 1 .5 7
E 7 F A S F a s  ( T N F  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  6 )
+ 1 .4 3 2 .2 6 - 2 . 8 0 - 1 . 7 2
E 8 F A S L G F a s  l ig a n d  ( T N F  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  6 ) + - 2 . 1 6 - 2 . 0 5 1 9 . 4 6 1 1 . 7 5
E 9
G A D D 4 5
A G r o w t h  a r r e s t  a n d  D N A - d a m a g e - i n d u c i b l e ,  a lp h a
+ - 1 . 0 3 1 .5 4 2 .1 3 4 . 3 3
E 1 0 H R K
H a r a k i r i ,  B C L 2  i n t e r a c t in g  p r o t e in  ( c o n t a i n s  o n ly  B H 3  
d o m a in )
+ - 3 . 8 1 2 .2 0 1 .3 5 - 1 . 8 3
E l l I G F 1 R I n s u l in - l i k e  g r o w t h  f a c t o r  1  r e c e p t o r - 1 .4 2 - 1 . 9 5 1 .2 3 4 . 2 4
E 1 2 L T A L y m p h o t o x in  a lp h a  ( T N F  s u p e r f a m i l y ,  m e m b e r  1 ) + - 3 . 4 8 - 7 . 8 5 2 8 . 4 9 1 7 . 2 1
F I L T B R L y m p h o t o x in  b e t a  r e c e p t o r  ( T N F R  s u p e r f a m i ly ,  m e m b e r  3 ) + 1 .0 2 - 1 . 0 9 1 .1 5 - 1 . 2 0
F 2 M C L 1 M y e lo id  c e l l  l e u k e m ia  s e q u e n c e  1 ( B C L - r e l a t e d ) - - 1 . 0 1 - 2 . 4 2 4 .1 5 7 .7 5
F 3 N 0 L 3 N u c le o la r  p r o t e in  3  ( a p o p t o s i s  r e p r e s s o r  w i t h  C A R D  d o m a in ) - - 1 . 2 0 2 .2 8 - 2 . 0 5 - 1 . 5 1
F 4 P Y C A R D P Y D  a n d  C A R D  d o m a in  c o n t a i n i n g + - 1 . 1 0 - 2 . 5 9 2 .3 0 6 .9 9
F 5 R IP K 2 R e c e p t o r - i n t e r a c t i n g  s e r i n e - t h r e o n in e  k in a s e  2 - 1 .0 2 1 .8 8 - 2 . 7 8 - 1 . 9 1
F 6 T N F T u m o r  n e c r o s i s  f a c t o r
+ - 1 . 7 5 - 1 0 . 1 4 4 .9 3 2 5 . 7 2
T N F R S F 1
- 1 . 7 5 - 2 . 5 7 7 6 . 2 4 2 5 . 0 2
F 7 O A T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 0 a
+
T N F R S F 1
1 .1 1 1 .7 0 - 1 . 3 8 1 .1 4
F 8 O B T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 0 b
T N F R S F 1
1 .6 8 1 .0 1 3 1 . 1 8 1 1 . 3 5
F 9 I B T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  l i b
T N F R S F 1
1 .2 4 - 2 . 0 7 2 .3 8 2 . 2 7
F 1 0 A T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1 A
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Pro  (+) o r  
Anti (-) 
A p o p to tic
U87 3 
D ay
+Cisp latin  
-G am m a  





+Gam m a  
vs 3 Day  
Control
U87 7  
Day
+Cisplatin  
-G am m a  





+G am m a  
vs 7  D ay  
Control
F l l T N F R S F 2 1 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  2 1 + - 1 . 0 3 1 .4 3 - 3 . 8 6 - 3 . 2 4
F 1 2 T N F R S F 2 5 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  2 5 + - 1 . 3 9 1 .4 0 - 1 . 4 3 3 .2 8
G 1 C D 2 7 C D 2 7  m o le c u le - - 1 . 7 4 - 2 . 6 8 1 8 . 9 3 9 7 . 3 4
G 2 T N F R S F 9 T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  9
+ 1 .5 4 - 1 . 1 7 - 2 . 9 8 - 1 . 3 3
G 3 T N F R S F 1 0 T u m o r  n e c r o s i s  f a c t o r  ( l i g a n d )  s u p e r f a m i l y ,  m e m b e r  1 0
+ - 4 . 1 7 - 1 . 7 6 7 . 4 8 4 . 5 2
G 4 C D 7 0 C D 7 0  m o le c u le + 1 .1 0 - 1 . 1 2 - 1 . 5 1 - 1 . 3 5
G 5 T N F R S F 8 T u m o r  n e c r o s i s  f a c t o r  ( l i g a n d )  s u p e r f a m i l y ,  m e m b e r  8 + 2 .0 6 2 .1 7 6 .4 2 1 4 . 0 7
G 6 T P 5 3 T u m o r  p r o t e in  p 5 3
+ 1 .0 5 1 .4 2 - 3 . 4 5 - 3 . 4 9
G 7 T P 5 3 8 P 2 T u m o r  p r o t e in  p 5 3  b in d in g  p r o t e in ,  2
+ - 1 . 0 9 1 .4 2 - 1 . 8 4 - 1 . 2 6
G 8 T P 7 3 T u m o r  p r o t e in  p 7 3
+ - 1 . 0 7 - 5 . 5 1 4 9 . 9 5 4 8 . 6 7
G 9 T R A D D T N F R S F l A - a s s o c i a t e d  v ia  d e a t h  d o m a in + - 1 . 2 0 1 .2 8 - 1 . 1 1 1 .4 4
G 1 0 T R A F 2 T N F  r e c e p t o r - a s s o c ia t e d  f a c t o r  2 - - 1 . 5 5 - 2 . 2 2 1 .8 4 1 .5 4
G i l T R A F 3 T N F  r e c e p t o r - a s s o c i a t e d  f a c t o r  3
+ - 1 . 1 8 - 1 . 4 4 1 .1 4 1 .2 1
G 1 2 T R A F 4 T N F  r e c e p t o r - a s s o c ia t e d  f a c t o r  4 - 1 .0 5 - 1 . 0 0 - 1 . 0 5 - 1 . 0 9
H O I B 2 M B e t a - 2  m i c r o g lo b u l in N / A 1 .3 2 1 .3 4 - 1 . 1 9 1 .0 3
H 0 2 H P R T 1 H y p o x a n t h i n e - g u a n in e  p h o s p h o r i b o s y l t r a n s f e r a s e N / A - 1 . 0 1 1 .1 9 - 1 . 7 5 - 1 . 9 4
H 0 3 R P L 1 3 A 6 0 S  r ib o s o m a l  p r o t e in  L 1 3 a N / A - 1 . 1 3 - 2 . 0 3 3 .4 2 3 . 0 4
H 0 4 G A P D H G l y c e r a l d e h y d e  3 - p h o s p h a t e  d e h y d r o g e n a s e N / A - 1 . 1 6 1 .2 7 - 1 . 6 4 - 1 . 6 2
H 0 5 A C T B B e t a - a c t in
N / A - 1 . 0 4 1 .4 2 - 3 . 0 3 - 3 . 2 2
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Figure 5: U87 3 Day Cisplatin Plus Gamma Irradiation Fold Regulation vs. 3 Day Control





Figure 6: U87 7 Day Cisplatin Only Fold Regulation vs. 7 Day Control
7 Day +Cisplatin -Gamma vs. 7 Day Control
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Figure 8: U251 3 Day Cisplatin Only Fold Regulation vs. 3 Day Control
3 Day +Cisplatin -Gamma vs. 3 Day Control
1 A
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7 Day +Cisplatin -Gamma vs. 7 Day Control
Figure 10: U251 7 Day Cisplatin Only Fold Regulation vs. 7 Day Control
Figure 11: U251 7 Day Cisplatin Plus Gamma Irradiation Fold Regulation vs. 7 Day Control
7 Day +Cisplatin +Gamma vs. 7 Day Control
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